Chemoresistance remains a major challenge in the treatment of ovarian cancer. As part of a survival mechanism, tumor cells have been shown to release proangiogenic factors, such as vascular endothelial growth factor (VEGF), through a mechanism that involves the upregulation of hypoxia-induced factor (HIF)-1α. The objective of this study was to compare the expression of VEGF and its receptors (R1 and R2) as well as HIF-1α in chemoresistant epithelial ovarian cancer (EOC) cells to their chemosensitive counterparts and determine their impact on angiogenesis.
Methods:
Two human EOC cell lines, MDAH-2774 and SKOV-3, and their cisplatin- or taxotere-resistant counterparts were used. Total RNA and protein were subjected to real-time reverse transcriptase–polymerase chain reaction, immunoprecipitation/Western blot and enzyme-linked immunosorbent assay to evaluate the expression of VEGF, VEGF receptors (R1 and R2), and HIF-1α. Angiogenesis was assessed with an in vitro angiogenesis assay. Data were analyzed using independent Student t tests and chi-square.
Results:
Both taxotere- and cisplatin-resistant MDAH-2774 and SKOV-3 EOC cell lines manifested a significant decrease in VEGF, VEGF receptors, HIF-1α messenger RNA, and protein levels as compared to their chemosensitive counterparts. There was a significant decrease in the number and thickness of polygon blood vessel formation in chemoresistant EOC cells compared to chemosensitive counterparts.
Conclusion:
Cisplatin- and taxotere-resistant EOC cells are characterized by lower VEGF, VEGF receptors, and HIF-1α, and decreased angiogenesis. These findings may indicate a decrease in drug delivery at the tumor site, hence allowing the persistence of chemoresistant EOC cells.
ACS. Cancer Facts & Figures 2015. 2015edn. Atlanta, GA: American Cancer Society; 2015.
2.
LeahyY. Are serum protein biomarkers effective in detecting ovarian cancer in its early stages?Clin J Oncol Nurs. 2009;13(4):443–445. doi:10.1188/09.CJON.443-445
3.
MarkmanM. Pharmaceutical management of ovarian cancer: current status. Drugs. 2008;68(6):771–789.
4.
BianCYaoKLiLYiTZhaoX. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Arch Gynecol Obstet. 2015;293(1):163–168. doi:10.1007/s00404-015-3813-z.
5.
CarmelietPJainRK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417–427. doi:10.1038/nrd3455
6.
HicklinDJEllisLM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027. doi:10.1200/JCO.2005.06.081.
7.
Masoumi MoghaddamSAminiAMorrisDLPourgholamiMH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2012;31(1-2):143–162. doi:10.1007/s10555-011-9337-5.
8.
RavaudAWallerandHCulineS. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol. 2008;54(2):315–325. doi:10.1016/j.eururo.2008.04.056
9.
FontaniniGFavianaPLucchiM. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer. 2002;86(4):558–563. doi:10.1038/sj.bjc.6600130.
ErikssonACaoRPawliukR. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer cell. 2002;1(1):99–108.
12.
OtrockZKMakaremJAShamseddineAI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007;38(3):258–268. doi:10.1016/j.bcmd.2006.12.003.
13.
SharmaPSSharmaRTyagiT. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Current Cancer Drug Targets. 2011;11(5):624–653.
BelotteJFletcherNMAwonugaAO. The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer. Reprod Sci. 2014;21(4):503–508. doi:10.1177/1933719113503403.
16.
SaedGMAli-FehmiRJiangZL. Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol Oncol. 2010;116(2):276–281. doi:S0090-8258(09)00919-6 [pii] 10.1016/j.ygyno.2009.11.004.
17.
MaloneJMSaedGMDiamondMPSokolRJMunkarahAR. The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer. Am J Obstet Gynecol. 2006;194(4):1110–1116; discussion 1116-1118. doi: S0002-9378(05)02717 -1 [pii] 10.1016/j.ajog.2005.12.019.
18.
BakerEKEl-OstaA. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res. 2003;290(2):177–194.
19.
CunninghamDPyrhonenSJamesRD. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1413–1418. doi:10.1016/S0140-6736(98)02309-5.
20.
KimJJTannockIF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5(7):516–525. doi:10.1038/nrc1650.
21.
MilkiewiczMIspanovicEDoyleJLHaasTL. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol. 2006;38(3):333–357. doi:10.1016/j.biocel.2005.10.006.
22.
BouckNStellmachVHsuSC. How tumors become angiogenic. Adv Cancer Res. 1996;69:135–174.
23.
HanahanDFolkmanJ. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–364.
24.
MillauerBShawverLKPlateKHRisauWUllrichA. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994;367(6463):576–579. doi:10.1038/367576a0.
25.
SinghRKGutmanMBucanaCDSanchezRLlansaNFidlerIJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A. 1995;92(10):4562–4566.
26.
VeikkolaTAlitaloK. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 1999;9(3):211–220. doi:10.1006/scbi.1998.0091.
27.
GatelySTwardowskiPStackMS. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A. 1997;94(20):10868–10872.
28.
RakJFilmusJFinkenzellerGGrugelSMarmeDKerbelRS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 1995;14(4):263–277.
29.
ChaSTChenPSJohanssonG. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res. 2010;70(7):2675–2685. doi:10.1158/0008-5472.CAN-09-2448.
30.
ManaloDJRowanALavoieT. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105(2):659–669. doi:10.1182/blood-2004-07-2958.
31.
AghajanianCBlankSVGoffBA. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. doi:10.1200/JCO.2012.42.0505.
32.
PerrenTJSwartAMPfistererJ. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496. doi:10.1056/NEJMoa1103799.
33.
StocklerMRHilpertFFriedlanderM. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13):1309–1316. doi:10.1200/JCO.2013.51.4240.
34.
ColemanRLBradyRFHerzogTJ. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer. Presented at: Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer 2015; March 28–31, 2015; Chicago, IL. Abstract 3 (late breaking).
35.
KimJAChoKBKimMR. Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells. Cancer Lett. 2008;268(2):225–232. doi:10.1016/j.canlet.2008.03.050.
36.
HuGRyanSZhuY. Vascular endothelial growth factor modulates cisplatin sensitivity in human ovarian carcinoma cells. Cancer Ther. 2003;1:31–37.
37.
GadducciASergiampietriCLanfrediniNGuiggiI. Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol Endocrinol. 2014;30(4):266–271. doi:10.3109/09513590.2013.871525.
38.
WeissABonvinDBerndsenRH. Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci Rep. 2015;5:8990. doi:10.1038/srep08990.
39.
RussellSDuquetteMLiuJDrapkinRLawlerJPetrikJ. Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer. FASEB J. 2015;29(2):576–588. doi:10.1096/fj.14-261636.
40.
Cruz-MunozWDi DesideroTManS. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis. 2014;17(3):661–673. doi:10.1007/s10456-014-9422-9.
